SCHEDULE 13G: BlackRock Discloses 5.6% Stake in ORIC Pharmaceuticals
Beneficial Ownership Report
BlackRock, Inc. has reported a beneficial ownership of 5.6% of ORIC Pharmaceuticals Inc.'s common stock as of December 31, 2025.
Summary
- BlackRock, Inc. filed a Schedule 13G, indicating beneficial ownership of ORIC Pharmaceuticals Inc. common stock.
- BlackRock beneficially owns 5,473,145 shares, representing 5.6% of the class.
- BlackRock holds sole voting power over 5,388,358 shares and sole dispositive power over 5,473,145 shares.
- The filing was made by BlackRock, Inc. as a parent holding company, with several subsidiaries identified as having beneficial ownership.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral. This is a standard regulatory disclosure of an institutional ownership stake, not indicative of positive or negative company performance or strategic shifts.
Future Outlook
NA
Industry Context
This filing reflects a routine disclosure by a major institutional investor, BlackRock, Inc., regarding its passive stake in ORIC Pharmaceuticals Inc. Such disclosures are common for large asset managers who cross the 5% ownership threshold in publicly traded companies, indicating a significant but non-controlling investment. It provides transparency on institutional holdings within the pharmaceutical sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, revoking the previous one dated April 30, 2023, and appointing new attorneys-in-fact for executing various SEC filings. This ensures proper authorization for regulatory compliance. | 2025-01-21 | This is a standard internal corporate governance update for BlackRock, ensuring authorized personnel can execute necessary regulatory filings. It has no direct impact on ORIC Pharmaceuticals Inc.'s corporate governance or operations. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can be viewed as a routine disclosure of a passive investment.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney for BlackRock, Inc. was dated. |
| 2025-01-21 | New Power of Attorney for BlackRock, Inc. was executed, revoking the previous one. |
| 2025-12-31 | Date of the event which requires filing of this statement, representing the reporting period end for beneficial ownership. |
| 2026-01-21 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
ORIC Pharmaceuticals, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.